Key TakeawaysNovartis posted second-quarter net sales and adjusted profit that beat analysts' expectations.The drugmaker upped its full-year core operating income outlook for the second time in as many quarters.Novartis now expects fiscal 2024 core operating income to grow by a mid- to high-teen-percentage rate, up from a low-double-digit to mid-teen rate. Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and ra ...